- Bisphosphonate use was associated with significant reduction in the risk for endometrial cancer vs no use, but not ovarian cancer.
- Bisphosphonate use for >1 year reduces the risk by 43%, and by 47% in postmenopausal women.
Why this matters
- Published data on the association between bisphosphonate use and ovarian/endometrial cancer are inconsistent.
- Meta-analysis of 7 studies identified after a search on MEDLINE, EMBASE, and Web of Science databases.
- 6471 women with endometrial cancer from 7 studies (213,920 participants) and 6783 women with ovarian cancer from 4 studies (105,507 participants) were included.
- Funding: None.
- Any use of bisphosphonates was associated with 27% reduction in the risk for endometrial cancer (relative risk [RR], 0.73; P=.012) vs no use.
- In postmenopausal women, bisphosphonate use was associated with 47% lower risk for endometrial cancer (RR, 0.53; P=.012) vs no bisphosphonates.
- Bisphosphonate use for >1 year was associated with significant reduction in endometrial cancer (RR, 0.57; P=.024).
- Use of bisphosphonates was not associated with risk for ovarian cancer (RR, 0.81; P=.227).
- Moderate to high heterogeneity.
- Data on bisphosphonate and tumor type were lacking.